Scarica l'app Stockscreener
0.7676
6.95%
0.0499
Dopo l'orario di chiusura:
.76
-0.0076
-0.99%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.7177
Aprire:
$0.8
Volume 24 ore:
1.11M
Relative Volume:
1.52
Capitalizzazione di mercato:
$37.60M
Reddito:
-
Utile/perdita netta:
$-40.56M
Rapporto P/E:
-0.6561
EPS:
-1.17
Flusso di cassa netto:
$-35.28M
1 W Prestazione:
+2.95%
1M Prestazione:
-17.91%
6M Prestazione:
-45.56%
1 anno Prestazione:
-64.30%
Intervallo 1D:
$0.7201
$0.8082
Intervallo di 1 settimana:
$0.703
$0.815
Portata 52W:
$0.703
$2.46
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Nome
Pds Biotechnology Corporation
Settore
Industria
Telefono
800-208-3343
Indirizzo
303A COLLEGE ROAD EAST, PRINCETON
Confronta PDSB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
0.7676 | 39.27M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.15 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.00 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.93 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
915.36 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.60 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-11-01 | Iniziato | B. Riley Securities | Buy |
| 2021-06-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Iniziato | Alliance Global Partners | Buy |
| 2020-03-09 | Iniziato | Noble Capital Markets | Outperform |
| 2019-10-24 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Pds Biotechnology Corporation Borsa (PDSB) Ultime notizie
PDS Biotech secures FDA meeting to discuss accelerated approval pathway By Investing.com - Investing.com Nigeria
PDS Biotech secures FDA meeting to discuss accelerated approval pathway - Investing.com
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration ('FDA”) - The Manila Times
PDS Biotech (Nasdaq: PDSB) Plans FDA Talk on PFS Endpoint in VERSATILE-003 Trial - Stock Titan
How supply chain issues affect PDS Biotechnology Corporation stockGlobal Markets & Stock Timing and Entry Methods - Newser
Energy Moves: How interest rate cuts could boost PDS Biotechnology Corporation stock2025 Volatility Report & Capital Efficiency Focused Ideas - moha.gov.vn
Adversity is less terrifying than hope: PDS Biotechnology Corporation (PDSB) - Setenews
B. Riley Cuts PDS Biotechnology (NASDAQ:PDSB) Price Target to $3.00 - Defense World
History Review: How interest rate cuts could boost PDS Biotechnology Corporation stockPortfolio Growth Summary & Precise Buy Zone Tips - BỘ NỘI VỤ
PDS Biotechnology price target lowered to $3 from $5 at B. Riley - Yahoo Finance
B. Riley Securities Maintains PDS Biotechnology (PDSB) Buy Recommendation - Nasdaq
B. Riley Adjusts Price Target on PDS Biotechnology to $3 From $5, Maintains Buy Rating - MarketScreener
Can PDS Biotechnology Corporation stock reach $100 price targetMarket Performance Report & Growth Focused Investment Plans - newser.com
PDS Biotechnology Shares Face Market Pressure Despite Clinical Promise - Ad-hoc-news.de
What dividend safety score for PDS Biotechnology Corporation stock2025 Market Overview & Real-Time Volume Analysis Alerts - newser.com
Why PDS Biotechnology Corporation stock is recommended by analysts2025 Top Decliners & Growth Focused Stock Reports - newser.com
Earnings visualization tools for PDS Biotechnology CorporationOil Prices & Verified Technical Signals - newser.com
PDS Biotechnology Corporation’s volatility index tracking explainedInflation Watch & Breakout Confirmation Alerts - newser.com
Advanced analytics toolkit walkthrough for PDS Biotechnology CorporationCPI Data & Daily Oversold Bounce Ideas - newser.com
Is PDS Biotechnology Corporation stock a good choice for value investorsInflation Watch & Safe Entry Point Identification - newser.com
It makes sense and dollars to buy PDS Biotechnology Corporation (PDSB) stock - Setenews
Is PDS Biotechnology Corporation stock entering bullish territoryJuly 2025 Highlights & Consistent Growth Equity Picks - newser.com
PDS Biotechnology Corp (EU6.DU) stock price, news, quote and history - Yahoo Finance Singapore
Tools to assess PDS Biotechnology Corporation’s risk profilePortfolio Performance Report & Consistent Return Investment Signals - newser.com
Multi factor analysis applied to PDS Biotechnology CorporationWeekly Volume Report & Weekly Chart Analysis and Guides - newser.com
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2025 Earnings Call Transcript - Insider Monkey
Will PDS Biotechnology Corporation stock go up soonWeekly Investment Recap & AI Based Buy and Sell Signals - newser.com
Will PDS Biotechnology Corporation stock reach all time highs in 2025Earnings Growth Summary & Long-Term Safe Return Strategies - newser.com
PDS Biotechnology: Q3 Earnings Snapshot - New Haven Register
PDS Biotechnology Trims Losses And Aims For Accelerated Drug Approval - Finimize
PDS Biotechnology: Promising Trial Results and Financial Update - TipRanks
Earnings call transcript: PDS Biotech beats EPS expectations in Q3 2025 - Investing.com UK
HC Wainwright & Co. Maintains PDS Biotechnology (PDSB) Buy Recommendation - Nasdaq
PDS Biotechnology Corp (PDSB) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Q3 2025 Earnings Report - MarketBeat
Earnings call transcript: PDS Biotech beats EPS expectations in Q3 2025 By Investing.com - Investing.com South Africa
PDS Biotechnology Corporation (PDSB) Q3 FY2025 earnings call transcript - Yahoo Finance
PDS biotechnology Q3 net loss narrows on lower operating expenses - MarketScreener
PDS Biotechnology Corporation Completes VERSATILE-002 Phase 2 Trial, Pursues Expedited Approval for HPV16-Positive Head and Neck Cancer Treatment - Quiver Quantitative
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update - The Manila Times
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[8-K] PDS Biotechnology Corp Reports Material Event | PDSB SEC FilingForm 8-K - Stock Titan
PDS Biotech (Nasdaq: PDSB) to seek accelerated approval in VERSATILE-003 on 6.3-month PFS - Stock Titan
Pds Biotechnology Corporation Azioni (PDSB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pds Biotechnology Corporation Azioni (PDSB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Glover Stephen C. | Director |
Feb 28 '25 |
Buy |
1.66 |
15,061 |
25,001 |
78,851 |
0.93%
1.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):